业绩总结 - 2020年第一季度的调整现金流（非GAAP）为298百万美元，第四季度为423百万美元[7] - 2020年第一季度的调整EBITDA（非GAAP）为356百万美元，第四季度为434百万美元[7] - 2020年第一季度的调整现金收入（非GAAP）为382百万美元，第四季度为484百万美元[7] - 2020年第一季度的净现金提供来自经营活动（GAAP）为471百万美元，第四季度为566百万美元[7] - 2020年第一季度的总特许权使用费收入为544百万美元，第四季度为627百万美元[7] - 2020年第一季度的非控股权益分配为161百万美元，第四季度为143百万美元[7] - 2020年第四季度的HIV特许权使用费收入为4,257百万美元，同比下降7%[14] 现金流与成本 - 2020年第四季度的运营和专业成本支付为50百万美元，占调整现金收入的10.4%[19] - 2020年第四季度的持续开发阶段资金支付降至2百万美元，较2019年第四季度的16百万美元显著下降[20] - 2020年第四季度的净利息支付为1百万美元，较2019年第四季度的50百万美元大幅减少[21] - 截至2020年12月31日，Royalty Pharma的现金、现金等价物和可交易证券总额为20亿美元，长期债务为58亿美元[22] 未来展望与交易 - 2021年第一季度，Royalty Pharma进行的三笔交易导致现金流出5.02亿美元[22] - 2021年1月19日，Royalty Pharma宣布收购Minerva的seltorexant特许权，前期付款为6000万美元，潜在里程碑付款最高可达9500万美元[22] - 2021年3月29日，Royalty Pharma向Biohaven支付1亿美元，以实现zavegepant的里程碑，至此zavegepant的总融资达到2.5亿美元[23] - 2021年3月31日，Royalty Pharma与GlaxoSmithKline达成协议，收购cabozantinib产品的特许权，前期付款为3.42亿美元，额外付款最高可达5000万美元[25] 公司背景与市场策略 - Royalty Pharma成立于1996年，是生物制药特许权的最大买家，拥有超过45种商业产品的特许权组合[44] - Royalty Pharma的组合包括AbbVie和J&J的Imbruvica、Astellas和Pfizer的Xtandi等多个知名疗法[44] - 公司通过与小型和中型生物技术公司及大型制药公司合作，直接和间接资助生物制药行业的创新[44] - Royalty Pharma在收购现有特许权的同时，也与公司合作共同资助后期临床试验和新产品发布[44] - 公司在未来的增长机会和市场增长方面持乐观态度，但前瞻性声明并不保证业绩[47] - 前瞻性声明基于管理层当前的信念和假设，可能受到多种风险和不确定性的影响[47] - 公司未对第三方来源的信息进行独立验证，且不对其准确性或完整性作出任何声明[48] - 所有市场数据均涉及多项假设和限制，无法保证其准确性或可靠性[48]

Royalty Pharma plc (NASDAQ:RPRX) Q1 2021 Earnings Conference Call May 11, 2021 8:00 AM ET Company Participants George Grofik - Senior Vice President and Head, Investor Relations and Communications Pablo Legorreta - Founder and Chief Executive Officer Marshall Urist - Executive Vice President and Co-Head, Research and Investments Jim Reddoch - Executive Vice President and Co-Head, Research and Investments & Chief Scientific Officer Terry Coyne - Executive Vice President and Chief Financial Officer Chris Hite ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39329 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 110 East 59 Street th ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) (State or other jurisdiction of incorporation or organization) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39329 Royalty Pharma plc (Exact name of registrant as specified in its ...

Royalty Pharma plc (NASDAQ:RPRX) Q4 2020 Earnings Conference Call February 17, 2021 8:00 AM ET Company Participants George Grofik - Senior Vice President, Head of Investor Relations and Communications Pablo Legorreta - Founder and Chief Executive Officer Jim Reddoch - Executive Vice President and Co-Head of Research and Investments Marshall Urist - Executive Vice President and Co-Head of Research and Investments Terry Coyne - Executive Vice President and Chief Financial Officer Chris Hite - Vice Chairman Co ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 For the transition period from to Commission file number 001-39329 Royalty Pharma plc (Exact name of registrant as specified in its charter) England and Wales Not applicable (State or othe ...

Royalty Pharma plc (NASDAQ:RPRX) Q3 2020 Results Conference Call November 11, 2020 8:00 AM ET Company Participants George Grofik - SVP, Head, IR and Communications Pablo Legorreta - Founder and CEO Jim Reddoch - EVP and Head of Research & Investments Terry Coyne - EVP and CFO Chris Hite - Vice Chairman Marshall Urist - SVP, Research and Investments Conference Call Participants Geoff Meacham - Bank of America Steve Scala - Cowen David Risinger - Morgan Stanley Chris Schott - JP Morgan Greg Gilbert - Truist N ...

ROYALTY PHARMA ROYALTY PHARMA Royalty Pharma plc Q3 2020 Financial Results November 11, 2020 2 Forward Looking Statements & Non-GAAP Financial Information This presentation has been prepared by Royalty Pharma plc (the "Company"), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are ma ...

Royalty Pharma plc (NASDAQ:RPRX) Q2 2020 Earnings Conference Call August 12, 2020 8:00 AM ET Company Participants George Grofik - Senior Vice President, Head of Investor Relations & Communications Pablo Legorreta - Founder & Chief Executive Officer Marshall Urist - Senior Vice President, Research & Investments Terry Coyne - Executive Vice President, Chief Financial Officer Conference Call Participants Geoff Meacham - Bank of America Chris Schott - JPMorgan Steve Scala - Cowen Gregg Gilbert - Truist David Ri ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39329 Royalty Pharma plc (Exact name of registrant as specified in its charter) England and Wales Not applicable (State or other ...